Availability and reimbursement of biological products for severe asthma in Bulgaria.

ABSTRACT:

Objectives

This study aims to analyze the reimbursement and cost of biological therapy for severe asthma in Bulgaria during 2014-2019 from the perspective of the National Health Insurance Fund.

Methods

It is a retrospective, Marco-costing, top-down study of the expenditures for biological products for severe asthma. The changes in the cost paid by the National Health Insurance Fund per year, per product, and per patient during 2015-2020 were systematized and calculated. The utilization of biologicals was analyzed by calculating the defined daily dose/1000inh/day. Three databases were searched-the European Medicines Agency for the date of marketing authorization of biological products, National Council of Prices and Reimbursement for the date of their respective inclusion in

SUBMITTER: Milushewa P 

PROVIDER: S-EPMC7446259 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature